PT - JOURNAL ARTICLE AU - Wan, Shanshan AU - Qu, Gaojing AU - Yu, Hui AU - Zhu, Haoming AU - Huang, Guoxin AU - Chen, Lei AU - Zhang, Meiling AU - Liu, Jiangtao AU - Pei, Bin TI - Features of creatine-kinase in COVID-19 patients with different ages, clinical types and outcomes: A cohort study AID - 10.1101/2020.10.28.20221093 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.28.20221093 4099 - http://medrxiv.org/content/early/2020/11/01/2020.10.28.20221093.short 4100 - http://medrxiv.org/content/early/2020/11/01/2020.10.28.20221093.full AB - Objectives To study the features of creatine-kinase (CK) in COVID-19 patients with different ages, clinical types and outcomes and quantify the relationship between CK value and clinical type.Methods All laboratory confirmed COVID-19 patients hospitalized in Xiangyang No.1 People’s Hospital were included. Patients’ general information, clinical type, all CK values and outcome were collected.Results The peak median value of CK in cases aged ≥ 71 years old (appeared at T2) was higher than that in cases aged ≤ 70 years old. There was statistical difference between the two groups (P=0.001). Similarly, the peak in critical cases (appeared at T2) was higher than moderate and severe types, and significant difference were existed among moderate, severe, and critical types (P=0.000). Moreover, the peak value in death group (appeared at T2) was higher than those in survival group. Significant difference was also found between them (P=0.000). According to the optimal scale regression model, the CK value (P=0.000) and age (P=0.000) were associated with the clinical type.Conclusions Difference of the CK in different ages, clinical types, and outcomes were significant. The results of the optimal scale regression model are helpful to judge the clinical type of COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000031088Funding StatementNo external funding was received in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was unanimously approved by Ethics Committee of Xiangyang NO.1 people's hospital on February 12, 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnyone who wishes to obtain the original data of this study with reasonable purposes can contact the correspondent author via email.